Baxter Healthca Patent-Cliff Exposure & CMS Drug Spending Portfolio

Baxter Healthca (US): 74 reconciled FDA prescription therapies, $936.1M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies74
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$936.1M
2024 Medicare Part D Spend$41.0M
2024 Medicaid Spend$895.1M
California HCAI SB 17 Filings16 WAC filings (max 88.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.